Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 12/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NAT1 | P18440 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8534288 | 1.00 | PTGS2 (0.48) | PTGS2PTGS1ALOX5MEN1ALDH1A1 | |
| SCHEMBL8894309 | 0.89 | PTGS2 (0.52) | PTGS2PTGS1ALOX5MEN1ALDH1A1 | |
| SCHEMBL8992104 | 0.89 | PTGS2 (0.52) | PTGS2PTGS1ALOX5MEN1ALDH1A1 | |
| SCHEMBL8534273 | 0.85 | PTGS2 (0.55) | PTGS2PTGS1ALOX5MEN1ALDH1A1 | |
| SCHEMBL8534268 | 0.85 | PTGS2 (0.55) | PTGS2PTGS1ALOX5MEN1ALDH1A1 | |
| SCHEMBL8992131 | 0.79 | PTGS2 (0.48) | PTGS2PTGS1ALOX5MEN1ALDH1A1 | |
| SCHEMBL8895623 | 0.79 | PTGS2 (0.48) | PTGS2PTGS1ALOX5MEN1ALDH1A1 | |
| SCHEMBL8532127 | 0.77 | PTGS2 (0.46) | PTGS2PTGS1ALOX5MEN1ALDH1A1 | |
| SCHEMBL8532129 | 0.77 | PTGS2 (0.46) | PTGS2PTGS1ALOX5MEN1ALDH1A1 | |
| SCHEMBL8198993 | 0.77 | NAT1 (0.69) | PTGS2PTGS1ALOX5MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0434394-B1 | Compounds for treating inflammatory bowel disease | LILLY CO ELI (US) | 1998-08-05 | — | — | EP | disclosed |
| EP-0722729-A2 | Aryl-substituted rhodanines for treating multiple sclerosis | ELI LILLY AND COMPANY (US) | 1996-07-24 | — | — | EP | disclosed |
| EP-0391644-B1 | Aryl-substituted rhodanine derivatives | LILLY CO ELI (US) | 1996-06-19 | — | — | EP | disclosed |
| US-5387690-A | Method of treating inflammatory bowel disease | ELI LILLY AND COMPANY (US) | 1995-02-07 | — | — | US | disclosed |
| US-5356917-A | Antiischemic, antiinflammatory, antiarthritic agents, treat-ment of dystrophic mammals | ELI LILLY AND COMPANY (US) | 1994-10-18 | — | — | US | disclosed |
| US-5216002-A | Using benzyl substituted rhodanine derivatives as pure enantiomeric form | ELI LILLY AND COMPANY (US) | 1993-06-01 | — | — | US | disclosed |
| US-5158966-A | Aryl-substituted rhodanine derivatives | THE UNIVERSITY OF COLORADO FOUNDATION, INC. (US) | 1992-10-27 | — | — | US | disclosed |
| EP-0500337-A1 | Composition containing aryl-substituted rhodanine derivatives for the treatment of type I diabetes | UNIVERSITY OF COLORADO FOUNDATION, INC. (US) | 1992-08-26 | — | — | EP | disclosed |